GeoVax Labs, Inc. New closed at $0.17 on Nov 4, up 2.38%, 98.8% below its 52-week closing high. Volume of 285.8K shares was 0.92× its 20-day average (close to normal).
Split-adjusted performance: -41.8% over one month, -89.8% over six months, -98.8% over one year.
Short interest was 270.2K shares at the Oct 15 settlement, down 4.1% from the prior report (3.0% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| GOVXGeoVax Labs, Inc. New | $0.1680 | +2.38% | −89.8% | −100.0% | — | — | $1.5M | |
| ELABPMGC Holdings | $1.92 | −1.03% | −91.0% | — | −225.1% | — | $1.6M | Compare |
| KPTIKaryopharm Therapeutics | $0.0729 | −17.44% | −99.2% | −11.9% | −200.5% | — | $1.7M | Compare |
| KAPAKairos Pharma | $0.4897 | −3.03% | −87.4% | — | — | — | $1.7M | Compare |
| OGENOragenics | $0.3720 | +0.51% | −40.0% | — | — | — | $1.7M | Compare |
| GNPXGenprex | $2.14 | −7.36% | −89.1% | — | — | — | $1.8M | Compare |
| PPCBPropanc Biopharma | $1.79 | +4.68% | −92.9% | — | — | — | $1.8M | Compare |
| ARTLArtelo Biosciences | $2.27 | −5.42% | −90.9% | — | — | — | $1.2M | Compare |
| SBFMSunshine Biopharma | $2.65 | −3.28% | −98.8% | −1.6% | −16.9% | — | $2.0M | Compare |
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
